AstraZeneca Results Presentation Deck

Oncology Total Revenue ($m) 700 600 500 400 300 200 100 ■EM EROW Europe ■US Q3 5 4 37 308 Calquence 26% growth at CER to $1,839m in 9M 2023 2021 Q4 8 8 43 336 Q1 7 13 55 339 Q2 8 18 67 396 2022 Q3 12 18 79 457 Q4 17 20 86 465 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 41 CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World. Collaboration partners: Daiichi Sankyo (Enhertu). Q1 18 22 108 384 Q2 2023 24 27 117 485 Q3 28 30 128 468 Total Revenue ($m) 400 350 300 250 200 150 100 50 ☐EM 0 EROW ■ Europe ■US Q3 4 9 45 Enhertu >2x growth at CER to $919m in 9M 2023 2021 Q4 5 13 49 Q1 9 1 20 57 Q2 17 2 26 73 2022 Q3 APPENDIX | 9M 2023 Product Performance 25 2 31 124 Q4 29 3 33 151 Q1 38 3 55 161 Q2 2023 69 5 70 178 Q3 72 9 79 179

View entire presentation